logo-loader
NASDAQ:NMRD

Nemaura Medical Inc

Receive alerts
Market:
NASDAQ
Market Cap:
$159.6 m
Price
7.67 USD
Change
0.52%
52 weeks high
10.90
52 weeks low
2.50

Nemaura Medical is a medical technology company which has developed SugarBEAT® as a CE Marked non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) designed to help people with diabetes and pre-diabetics to better manage their glucose levels by spending more time in range. Insulin users can adjunctively use SugarBEAT® when calibrated with a finger-stick glucose reading.

SugarBEAT®

Nemaura Medical is a medical technology company developing SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) designed to help people with diabetes and pre-diabetics to better manage their glucose levels by spending more time in range. Insulin users can adjunctively use SugarBEAT® when calibrated with a finger-stick glucose reading.SugarBEAT® is a CE Marked non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) developed by Nemaura Medical Inc. designed to help people with diabetes and pre-diabetics to better manage their glucose levels by spending more time in range. Insulin users can adjunctively use SugarBEAT® when calibrated with a finger-stick glucose reading. SugarBEAT® is expected to launch in the United Kingdom in Q3 2019.

How it works

Passing a mild, non-perceptible electric current across the skin, sugarBEAT® painlessly draws a small amount of glucose molecules out of the interstitial fluid which naturally sits just below the top layer of skin, into a chamber within the patch.

The rechargeable transmitter then measures the glucose levels present within the chamber, and securely transmits this clinically relevant data every five minutes via Bluetooth to a pre-downloaded smart phone / device app.

Using a proprietary algorithm, the app then converts this data into glucose values. In order to better understand how glucose levels are affected by lifestyle factors, diet / medication / exercise / mood data can also be inputted into the app.

Key Points

- SugarBEAT® market launch due 2019 initially in United Kingdom, followed shortly thereafter by key European countries
- SugarBEAT® daily price expected to be comparable to cost of using glucose meters and strips
- SugarBEAT's® daily patch wear time allows for greater flexibility, with users able to wear on a non-consecutive day basis, unlike other glucose monitors which are designed to be continuously worn for 10-14 days
- SugarBEAT® expected to be non-invasive, painless and needle-free glucose trending device hence appeal to all persons with diabetes and pre-diabetics
- Each patch requires a 30-minute warm up, after which glucose readings are taken at five minute intervals throughout the day
- SugarBEAT® can additionally be used by insulin using persons with diabetes as an adjunctive glucose monitoring device when calibrated by a finger stick reading
- For more information, please visit the SugarBEAT® website by clicking here

US

Dr. Faz Chowdhury
Chief Executive Officer

Dr. Chowdhury has served as CEO and chair of the board of Nemaura Medical since formation in December 2013.  He is sole inventor on more than 50 granted and pending patents across over 15 technology platforms within the medical device and pharmaceutical sectors. He has authored Textbook Chapters on Nano-biosciences for Wiley and Elsevier, and serves on the Board of Medilink East Midlands, UK. Dr. Chowdhury holds a Masters in Microsystems and Nanotechnology from Cranfield University, UK, and Doctorate from the University of Oxford on nano-medicine and drug delivery.

Mr. Chris Avery
Vice President of Global Business Operations

Mr. Avery brings over 30 years of senior experience in the healthcare industry with a focus on launching products, establishing distribution channels, and developing international relationships. Previously, Mr. Avery co-founded DiagnoSys Medical, a UK medical device distribution company. In this role, Mr. Avery recruited, trained, and launched a field-based sales team and was responsible for negotiating the sale of the business to Home Diagnostics. Subsequently, Mr. Avery served as European Director and UK Managing Director at Home Diagnostic Inc. During his tenure at Home Diagnostics, Mr. Avery launched the company’s glucose monitoring portfolio, Orbus Stents and Animas insulin pumps, into the UK and helped build the European distribution network. Following Home Diagnostics Inc., Mr. Avery served as European Director and UK Managing Director at Nipro Diagnostics, a company dedicated to helping people with diabetes manage their disease by providing blood glucose monitoring systems and other diabetes products. While at Nipro, he re-focused the organization, delivering a new strategic direction and leadership that increased market penetration. Additionally, Mr. Avery established and managed the sales operations for the organization within various regions and oversaw distributors within the EU and Africa.  Most recently, Mr. Avery served as Senior Vice President of Business Development at Dallas Burston Ethitronix (DBE), where he was heavily involved in establishing and overseeing the Collaboration Agreement with Nemaura to commercialize SugarBEAT® in Europe. Mr. Avery oversaw the pre-launch phase for the distribution of SugarBEAT®, cultivating relationships with suppliers and diabetes key opinion leaders.

Mr. Bashir Timol
Chief Business Officer

Mr. Timol has served as member of the board of Nemaura Medical since formation in December 2013, and CBO since April 2018. He has co-founded, managed and funded several biotech and life science companies, and led the investment consortium that provided capital for the initial two funding rounds for Nemaura Medical. Mr. Timol obtained his Bachelor of Arts degree in Economics from the University of Central Lancashire, UK.

Dr. Fred Schaebsdau
Strategy & Business Development Advisor

Dr. Schaebsdau has over 15 years of executive level experience in the CGM, Blood Glucose Monitoring (BGM) and insulin delivery industries, which started in 2004 during his tenure with Abbott Diabetes Care, where he was a member of the M&A and post-merger integration teams responsible for the acquisition of TheraSense and its FreeStyle Navigator CGM. From September 2016 until January 2019, he was the General Manager of Dexcom Germany, which during his leadership became the fastest growing organization in Dexcom’s history achieving triple digit revenue and new patient growth every year. Two generations of CGM, G5 and G6, were successfully launched and negotiations with public insurers completed, which resulted in full reimbursement for >85% of the German population. From 2009 until August 2015, at Roche Diabetes Care, he was Senior Vice-President, Head of Global Strategy and Business Development, completing several strategic acquisitions, partnerships and licensing deals. In September 2015, he founded his own firm as exclusive distributor in Europe, the Middle East and Africa for UniStrip®, the world’s first generic blood glucose test strip. Since September 2015, he is a member of the Advisory Board of Peppermint Venture Partners. Dr. Schaebsdau studied Medicine at the University of Giessen and completed residencies in urology and surgery at the University of Chicago, University of Hannover and University of Freiburg. He is licensed to practice medicine in the U.S. and Germany. During his residency at the University of Hannover he conducted primary research in neurophysiology with a grant from the DFG (Deutsche Forschungsgemeinschaft) and completed his PhD. In 1993, he received an MBA from The Wharton School of the University of Pennsylvania.

Professor Karrar Khan
Director of Product Development

Professor Karrar Khan has over 35 years’ experience of drug discovery, pharmaceutical development, registration and managing pharmaceutical scientists. His experience includes 20 years as Head of Pharmaceutical Development for Boots Pharmaceuticals and Knoll and two years as Director for OSI where he managed their pharmaceutical development, analytical operations and DMPK. His expertise range from development for phase 1 to phase 3- 4 and significant experience of bringing prescription and OTC products to market on a global level (and has contributed to the registration and launch of over 60 pharmaceutical products). He is a Qualified person under the EC quality assurance directive.

David Scott
Director of Commercial Development and Licensing

David Scott is a trained chemist with over 35 years’ experience in the Pharmaceutical Industry spanning deal brokering, marketing, strategic planning, finance, business development and acquisitions. He is a skilled negotiator who has closed a number of major deals for inward and outward licensing for pharmaceutical products, delivery systems and technologies. He has also provided licensing training for a number of multinational pharma companies and training organisations and has published widely, (he is the author of the best-selling report, “Scrip’s Practical Guide to Pharmaceutical Licensing”). David is also an accredited “Certified Licensing Professional”.

Dr Richard Toon
Technical and Business Development Manager

Dr. Richard Toon is a chartered chemist who originally trained as a synthetic chemist and more recently trained in law. He has over 20 years of experience within pharmaceutical drug development including a number of years supervising ‘blue skies’ research projects for potential commercial exploitation within two large multinational Pharmaceutical Companies in the UK. More recently his career has focused on commercial law activities, such as contract negotiation and intellectual property issues, and business development. He has completed a number of large scale grant applications for industrial research, and is author of numerous publications pertaining to pharmaceutical development, and is also a Fellow of the Royal Society of Chemistry.